The global In-Vitro Fertilization Market size is expected to reach USD 33.9 billion by 2028, based on a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.5% from 2021 to 2028. The growth of the market is driven by the continuous efforts of the market players, government initiatives to make available better reimbursement policies, and an increase in the incidence of infertility due to lifestyle changes. Expansion of fertility procedures such as ICSI for treating infertility is expected to positively impact market growth in the near future.
Moreover, the availability of genomic
testing facilities that enable the prevention of the transfer of genetic
disorders during In Vitro Fertilization (IVF) is further expected to drive the
market. The insurance providers are providing coverage to IVF procedures owing
to an increase in the number of IVF treatments. This has led to competitive
pricing and has moderated the IVF treatment costs as the procedure has been a
successfully practiced technology, driving the market with more treatment
automation and standardization.
A decline in the Total Fertility Rate (TFR)
is a result of factors such as a behavioral shift in society. These factors
include a shift from rural to urban societies, the increased age of the first
birth, an increasing number of women in the labor force, postponement of
marriage, and lower marriage rates.
The in-person fertility treatments in U.S.
and Canada were suspended in March 2020 by the Canadian Fertility and Andrology
Society and American Society of Reproductive Medicine due to the COVID-19.
However, treatment is resuming in many countries with ease of COVID-19
restrictions, including the developing nations. Medicover Fertility, IVF center
in India, in July 2020 announced to resume the IVF procedures after initial
COVID risk assessment.
Related Press Release@ In-vitro
Fertilization Market Report
In-vitro
Fertilization Market Report Highlights
- Culture media dominated the market for IVF in terms
of revenue in 2020. A number of research activities are being undertaken
to improve the efficiency of culture media. For instance, Vitrolife
showcased its research on SpermFreeze solution at the American Society for
Reproductive Medicine (ASRM) that established the effectiveness of its
solution for sperm recovery and sperm-hyaluronic acid-binding
- Europe dominated the market for IVF in 2020.
Adoption of advanced technologies such as time-lapse microscopy by the
clinics, availability of affordable treatment, and adherence to medical
standards contribute to market growth in the region
- The APAC region is expected to witness increased
demand for IVF owing to fertility tourism and the availability of funding
for the treatment. In Japan, eligible couples can apply for co-funding for
a maximum of three cycles with USD 1,920 for each cycle
- The developing countries in Asia Pacific are
undertaking legal reforms to promote treatment adoption in the region. For
instance, in February 2020, the Government of India approved a bill for
the regulation of clinics offering reproduction assistance services,
including IVF, artificial insemination, and surrogacy
- In January 2020, Merck received Marketing
Authorization (MA) from the European Commission (EC) for its recombinant
human follicle-stimulating hormone, GONAL-f (follitropin alfa) 150 IU pen
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment